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Autotaxin is a secreted enzyme that produces most of the extracellular lysophosphatidate from lyso-
phosphatidylcholine, the most abundant phospholipid in blood plasma. Lysophosphatidate medi-
ates many physiological and pathological processes by signaling through at least six G-protein
coupled receptors to promote cell survival, proliferation and migration. The autotaxin/lysophos-
phatidate signaling axis is involved in wound healing and tissue remodeling, and it drives many
chronic inﬂammatory conditions from ﬁbrosis to colitis, asthma and cancer. In cancer, lysophos-
phatidate signaling promotes resistance to chemotherapy and radiotherapy, and increases both
angiogenesis and metastasis. Research into autotaxin inhibitors is accelerating, both as primary
and adjuvant therapy. Historically, autotaxin inhibitors had poor bioavailability proﬁles and thus
had limited efﬁcacy in vivo. This situation is now changing, especially since the recent crystal struc-
ture of autotaxin is now enabling rational inhibitor design. In this review, we will summarize cur-
rent knowledge on autotaxin-mediated disease processes including cancer, and discuss recent
advancements in the development of autotaxin-targeting strategies. We will also provide new
insights into autotaxin as an inﬂammatory mediator in the tumor microenvironment that promotes
cancer progression and therapy resistance.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction and overview
Lysophosphatidate (LPA) is the simplest phospholipid compris-
ing of a glycerol backbone, one fatty acid and a phosphate head
group. Its modest structure belies the multitude of physiological
and pathophysiological processes it mediates. Enzymatic genera-tion of LPA in plasma by lysophospholipase D activity was ﬁrst de-
scribed in 1986 by Akira et al. [1]. Autotaxin (ATX) is a 125-kDa
secreted glycoprotein that was ﬁrst isolated in 1992 from A2058
melanoma cells and described as an ‘‘autocrine motility factor’’
[2]. However, it would take another ten years before the plasma
lysoPLD activity was isolated and found to be identical to ATX
[3–5].
ATX, which is also known as ecto-nucleotide pyrophosphatase/
phosphodiesterase family member 2 (ENPP2), is one of seven
members of a pyrophosphatase/phosphodiesterase family. This
family of secreted enzymes has diverse functions, but was origi-
nally described as being capable of degrading nucleotide phos-
phates. However, ATX/ENPP2 is unique among the ENPPs because
of its lysoPLD activity. It generates LPA from lysophosphatidylcho-
line (LPC), the most abundant phospholipid in plasma with a
plasma concentration of >200 lM in human beings [6,7]
(Fig. 1A). Physiological plasma LPA levels are normally 61 lM in
healthy subjects [8], with the predominant LPA species being
C20:4 (39%), C18:2 (30%), and C18:1 (9%) [9]. The dynamic regula-
tion of LPA concentrations in the blood is established by the bal-
ance of LPA production by ATX [10] versus the degradation of
Fig. 1. Overview of autotaxin (ATX)/lysophosphatidate (LPA) signaling. (A) Extracellular ATX produces LPA from lysophosphatidylcholine (LPC) which is present in human
plasma at 200 lM via hydrolysis of the choline headgroup. LPA levels are normally 61 lM. (B) LPA signals through at least six G-protein coupled receptors to elicit a wide
range of cellular responses. Signaling through some of these receptors may be redundant and/or antagonistic, depending on which heterotrimeric G-protein is coupled to the
LPA receptor. Ga/b/c, G-protein alpha/beta/gamma subunits; Rho; Rho GTPase; ROCK, Rho-associated protein kinase; SRF, serum response factor; IP3, inositol triphosphate;
PLC, phospholipase C; DAG, diacylglycerol; PKC, protein kinase C; MAPK, mitogen-activated protein kinase; PI3K, phsophoinositide 3-kinase; Akt, protein kinase B; AC,
adenylate cyclase; cAMP, cyclic adenosine monophosphate.
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(LPPs), particularly LPP1 [11,12]. There may be some regulation
of LPA concentrations caused by the competitive inhibition of
LPA and sphingosine-1-phosphate (S1P) on ATX activity, but much
of this work was performed using low lM concentrations of ﬂuo-
rescent LPC analogs for ATX [10,13–15]. This would amplify the ef-
fects of the inhibition compared to the use of physiological
concentrations of LPC at >200 lM.
Five alternatively-spliced isoforms of ATX have been described
and all are catalytically active [16,17]. The original ATX described
in 1992 is termed ATXa, whereas the most abundant isoform is
ATXb and is the same isoform responsible for plasma lysoPLD
activity [18]. Full length ATX is synthesized as a pre-proenzyme
and is secreted by the classical secretory pathway [19,20]. Secreted
ATX binds to integrin or heparan sulfates on the cell surface
through its somatomedin-B-like (SMB) domains, which function
independently of its catalytic domain. This binding is believed to
localize LPA production adjacent to LPA receptors. The identity of
the cell-surface binding partner varies with cell type and is de-
scribed elsewhere [21–25]. This remains an area of active
investigation.
The crystal structures of mouse and rat ATX were solved in
2011 and have revealed much about the catalytic site of ATX
[22,26]. ATX has a preference for unsaturated and polyunsaturated
substrates [26]. There is a hydrophobic pocket in the catalytic do-
main, which is slightly U-shaped, and this is able to accommodate
the kinked acyl chains of unsaturated fatty acids compared to ex-
tended linear conformations of saturated fatty acids [26]. Althoughthere are other enzymatic processes that can generate LPA such as
the actions of secretory phospholipase A2 (sPLA2) or Ca2+-indepen-
dent phospholipase A2 (iPLA2b) on phosphatidate (PA) [27–29],
ATX is the major contributor of extracellular LPA. Levels of circulat-
ing LPA are decreased by about 50% in mice carrying a heterozy-
gous null-mutation for ATX [30,31]. Further, the contribution of
ATX to maintaining circulating LPA is demonstrated since its inhi-
bition causes a rapid decrease in plasma LPA of >95% [12,32,33].
The initial relation of ATX/LPA signaling with melanoma cells
resulted in much of the early research into ATX being concentrated
in the cancer ﬁeld, and progress has been regularly reviewed [34–
43]. In short, LPA signaling through at least six known G-protein-
coupled receptors (LPA1-6) stimulates cell survival and migration
through the relative activations of phosphatidylinositol 3-kinase
(PI3K), ERK1/2, mTOR, Ca2+-transients, Rac, Rho and Ras (Fig. 1B)
[44]. LPA increases vascular endothelial growth factor (VEGF) pro-
duction, which stimulates angiogenesis [45], a process necessary
for tumor progression. LPA decreases the expression of the tumor
suppressor, p53 [46], thus increasing cancer cell survival and divi-
sion. LPA levels as high as 10 lM have been found in ascites ﬂuid of
advanced ovarian cancer patients [8]. Mice that overexpress ATX,
LPA1, LPA2 or LPA3 in mammary epithelium develop spontaneous
metastatic mammary tumors [47]. Further, ATX is among the top
40 most up-regulated genes in metastatic cancers [48]. We discov-
ered that LPA produces resistance to the cytotoxic effects of paclit-
axel, a ﬁrst line treatment for breast cancer [49,50]. This was
conﬁrmed [51] and extended to carboplatin resistance [52]. ATX
and LPA also protect against radiation-induced cell death [7,53].
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the production of LPA by ATX could be a novel therapeutic inter-
vention for attenuating therapy resistance [7,44,54–60].
The ﬁndings from the cancer ﬁeld have been translated to other
disease models with inﬂammation being a common factor [6,9,61–
69]. The ATX/LPA signaling pathway is involved in chronic inﬂam-
matory conditions, and for some patients, inﬂammation could
underlie the development and progression of their cancers. This
is best understood in colon cancer models where chronic inﬂam-
mation of colonic mucosa leads to dysplasia and eventual cancer
[70–72]. We will summarize current knowledge on the embryo-
logic and physiologic roles of ATX and contrast this to the roles
of ATX in inﬂammation-mediated diseases, including cancer. We
will also discuss current progress on the development of ATX
inhibitor therapies and offer insights into the future directions of
the ﬁeld. A new model for ATX production in carcinomas will also
be proposed.
2. The embryological and physiological roles of ATX
ATX is a vital enzyme that is needed for early embryological
development. ATX knockout (KO) (ENPP2/) embryos die in utero
on average at day 9.5 with vascular and neural tube defects [30,73–
75]. In these mice, malformations in the allantois, neural tube and
headfold are detected by day 8.5, and by day 10.5 embryos become
necrotic and are reabsorbed [76]. Normally, extra-embryonic endo-
thelial cells remodel to create a vascular network that connects
with the embryo from days 8.5 to 9.5, allowing the yolk sac to
function as the main nutrient source. ENPP2/ embryos have in-
creased expression of VEGF mRNA, consistent with hypoxic condi-
tions in the absence of a functional vascular system [30,31]. This
illustrates the importance of LPA in vascular development.
Neural tube closure begins at day 8.5 and closure defects in EN-
PP2/ embryos have been attributed to a local deﬁciency in ATX
expression [30]. In ENPP2/ embryo explants, these folding
abnormalities are abrogated by exogenous addition of LPA [77].
The role of ATX in vascular and neural development has also been
conﬁrmed in zebraﬁsh [76,78]. ATX regulates oligodendrocyte dif-
ferentiation in developing zebraﬁsh hindbrain [79] and the correct
left–right asymmetry for normal organ morphogenesis through
Wnt-dependent pathways [80]. ENPP2+/mice are viable, and ex-
press both half the levels of ATX and LPA compared to normal mice.
However, they are hyper-responsive to hypoxia-induced vasocon-
striction and remodeling and they develop pulmonary hyperten-
sion [81].
The importance of ATX to proper neuronal development and
function is also reﬂected by high ATX mRNA in adult neuronal tis-
sues [82] (Fig. 2). ATX mRNA levels are also high in adipose tissues
(Fig. 2) and this will be discussed further in Section 4.3 [83]. Phys-
iologically, the most important role of ATX after birth is probably in
wound healing and tissue remodeling. LPA is a potent activator of
platelet aggregation and it stimulates the growth and migration of
ﬁbroblasts, vascular smooth muscle cells, endothelial cells and
keratinocytes [36]. In fact, ﬁbroblasts are second only to brain/
spinal cord tissue as the highest expressers of ATX mRNA (Fig. 2).
Increased ATX activity is found in blister ﬂuid where local produc-
tion of LPA promotes re-epithelialization [84]. ATX expression and
LPA production are increased in rabbit aqueous humor following
corneal freeze wounds [85]. Recently discovered roles for ATX in-
clude hair follicle morphogenesis [86], bone mineralization [87]
and myeloid differentiation in human bone marrow [88]. ATX/
LPA signaling also remodels luteal tissue in regressing corpora lu-
tea of cycling rats by recruiting phagocytes and proliferating ﬁbro-
blasts [89]. ATX expression is also upregulated in microglia in
response to oxidative stress. This protects microglia cells againstdamage from H2O2, an effect which is partially reversed in the
presence of the mixed LPA1/3 antagonist Ki16425 [90]. ATX is ex-
pressed in high endothelial venules (HEVs) in lymph nodes and
other secondary lymphoid tissues [91] and mediates lymphocyte
extravasation, which is crucial for maintaining immune homeosta-
sis [92,93]. However, in chronically inﬂamed tissues, ATX mediates
lymphocyte trafﬁcking and upregulates cytokine production in re-
sponse to repeated microinjuries and incomplete tissue repair [94–
96].
3. Acute physiological inﬂammation versus chronic
pathological inﬂammation
3.1. Overview of acute and chronic inﬂammation
Inﬂammation is a protective host response designed to rid the
organism of damaged and/or necrotic tissues and microbes. In
the absence of inﬂammation, injured tissues would not be repaired
and infections would go unchecked [97]. However, cellular mech-
anisms designed to eliminate foreign material as well as necrotic
cells also have the tendency to cause collateral damage to nearby
normal cells. Consequently, inﬂammation can be harmful in situa-
tions where it is inappropriately activated or poorly controlled. In
fact, in clinical medicine, much attention is given to the damaging
consequences of inﬂammation since they underlie many common
chronic diseases, such as rheumatoid arthritis, atherosclerosis, or-
gan ﬁbrosis, diabetes and obesity [98]. For this reason, pharmacies
abound with anti-inﬂammatory drugs, which ideally would control
the harmful sequelae of inﬂammation and not interfere with its
beneﬁcial effects.
The insult driving inﬂammation may be acute or chronic. Acute
inﬂammation has a rapid onset of action and lasts for hours or
days. This rapid host response serves to deliver leukocytes and
plasma protein to the site of tissue injury and/or infection. The red-
ness (rubor), warmth (calor) and swelling (tumor) of acute inﬂam-
matory reactions are caused by increases in blood ﬂow and
vascular permeability [99]. Circulating leukocytes, primarily neu-
trophils, then migrate to the site of injury under the inﬂuence of
chemotactic signals [100]. To eliminate the offending agents, acti-
vated leukocytes may release toxic metabolites and proteases
resulting in tissue damage causing pain (dolor). In contrast, chronic
inﬂammation can last from weeks to years. It may follow acute
inﬂammation or it may begin as a low-grade response without
any initial manifestations of an acute reaction. Tissue destruction
and attempts at repair often coexist in varying combinations
throughout its clinical course [101,102].
3.2. Termination of acute inﬂammation
Once the injurious stimulus has been successfully neutralized,
the inﬂammatory reaction subsides partly because the inﬂamma-
tory mediators are produced only as long as the stimulus persists.
More importantly, towards the end of acute inﬂammation, there is
a switch from pro-inﬂammatory to anti-inﬂammatory mediators.
Bioactive lipids such as lipoxin, resolvins and protectins, which
are derived from polyunsaturated fatty acids, contribute to the res-
olution of inﬂammation. The principal action of these molecules is
to inhibit leukocyte recruitment to the area of inﬂammation and
reduce vascular permeability. In short, the activation of anti-
inﬂammatory lipid mediators limits the progression of inﬂamma-
tion [98,103,104]. Under ideal circumstances, the site of acute
inﬂammation should be restored to normal upon complete resolu-
tion, both functionally and structurally. In tissues lacking regener-
ative potential, the site of injury is replaced by ﬁbrous tissue
through a process known as organization [104]. When the process
Fig. 2. ATX mRNA expression in normal human tissues as retrieved from the Genotype-Tissue Expression Portal [82] from the Broad Institute, Pilot Data 2013-01-31. ATX
expression varies greatly throughout the body, but it is very high in nervous and adipose tissue. RPKM, reads per kilobases per million (y-axis).
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there is a transition from acute to chronic inﬂammation ultimately
leading towards tissue destruction, loss of function, potential dys-
plasia and even cancer (Fig. 3).Infecons/ssue damage
Acute 
Inﬂammaon
Chronic 
Inﬂammaon
Tissue destrucon
Loss of funcon
Dysplasia and cancer
OrganizaonResoluon
Progression
Fig. 3. Overview of acute and chronic inﬂammation. In response to infections or
tissue damage, acute inﬂammatory processes attempt to restore homeostasis. If
successful, the inﬂammation will cause the tissue to recover completely (resolu-
tion), or undergo ﬁbrotic and/or other tissue remodeling processes that will
overcome the insult (organization). However, in the case of repeated microinjuries
or incomplete repair, acute inﬂammation can progress to chronic inﬂammation,
which can worsen the original pathogenesis.3.3. Cytokines
Numerous chemical mediators of inﬂammation have been iden-
tiﬁed. However, it is not yet fully understood how these mediators
act in coordination with others. Inﬂammatory mediators can be
classiﬁed into cell- and plasma protein-derived mediators, based
on their site of origin [105]. A full review of inﬂammatory media-
tors is beyond the scope of this article. Instead, we will focus
mainly on cytokines.
Cytokines orchestrate inﬂammatory cells such as lymphocytes,
macrophages and neutrophils to generate a proper immune re-
sponse. The term ‘‘cytokine’’ was proposed by Cohen et al. in
1974 to replace the misleading term ‘‘lymphokine’’ [106]. A deci-
sion was made in 1979 to adopt the interleukin (IL) nomenclature
to encompass the ever-growing list of identiﬁed cytokines [107].
There are two main groups of cytokines, namely pro-inﬂammatory
and anti-inﬂammatory. Pro-inﬂammatory cytokines are produced
predominately by activated macrophages. Anti-inﬂammatory cyto-
kines belong to the T cell-derived cytokines.
3.3.1. Pro-inﬂammatory cytokines
Prototypical pro-inﬂammatory cytokines include tumor necro-
sis factor alpha (TNF-a), IL-1, IL-6 and IL-8. TNF-a was originally
described as a tumor-cell killer and it is produced by activated
macrophages and natural killer cells following lipopolysaccharide
(LPS) exposure. Most cell types express TNF-a receptors with the
exception of erythrocytes [108]. In acute inﬂammation, TNF-a is
important in endothelial activation. TNF-a is a direct pyrogen
and potent inducer of systemic acute-phase responses associated
with infection or tissue injury [109]. IL-1a and IL-1b are the most
studied members of the IL-1 family and they are produced mainly
by mononuclear and epithelial cells as precursor proteins, which
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IL-1a and IL-1b function similarly to TNF-a in that they also trigger
fever and acute-phase responses. IL-6 is a small glycoprotein that is
produced by a variety of immune and non-immune cells such as
the endothelial cells, macrophages, ﬁbroblasts and lymphocytes.
It is also a potent inducer of fever and acute-phase responses.
[111,112]. Like IL-6, IL-8 is produced by macrophages, epithelial,
endothelial and airway smooth muscle cells. IL-8 was originally
known as neutrophil chemotactic factor since it induces neutrophil
migration to target tissues and induces phagocytosis [113]. IL-8 is
also a potent mediator of angiogenesis and its secretion is in-
creased by oxidative stress, which further drives the recruitment
of other pro-inﬂammatory cells to the site of inﬂammation [114].
3.3.2. Anti-inﬂammatory cytokines
Pro-inﬂammatory responses are typically mitigated by anti-
inﬂammatory cytokines like IL-4, IL-10 and IL-13. IL-4 and IL-13
utilize a common subunit in their receptors and consequently
share many biological functions. Activated T cells, mast cells and
natural killer cells produce both cytokines. IL-4 plays a fundamen-
tal role in the production of B cell-mediated IgE antibodies, which
mediate allergic reaction and defend against helminth infections.
More importantly, IL-4 inhibits macrophage activation and sup-
ports the differentiation of T helper type 2 (Th2) cells, which de-
crease pro-inﬂammatory responses. Similarly, IL-13 also induces
IgE production and inhibits inﬂammatory cytokine synthesis
[115–117]. IL-10, previously known as human cytokine synthesis
inhibitory factor (CSIF), is mainly produced by Th2 cells and mono-
cytes. The most important biological effect of IL-10 with respect to
immune modulation is to support the development of Th2 cells
while limiting Th1 pro-inﬂammatory responses [118].
4. The role of ATX in inﬂammatory diseases
ATX/LPA signaling is implicated in fueling many inﬂammatory
diseases. We will brieﬂy summarize recent discoveries into ATX-
mediated inﬂammation and ensuing pathology. As discussed previ-
ously, ATX is a part of the physiological wound healing response.
When the inﬂammation in these acute processes become chronic
in the context of repeated microinjury and incomplete repair,
ATX/LPA signaling fuels additional cytokine production and
recruitment into the local tissue environment, which can aggravate
the original disease.
4.1. Asthma and pulmonary ﬁbrosis
Asthma is chronic inﬂammatory disease of the airways charac-
terized by bronchospasm and reversible airﬂow obstruction. Acute
symptoms are treated with inhaled b2-agonists like salbutamol,
and asthma is typically managed with inhaled corticosteroids
[119]. Il-4, IL-5, IL-9 and IL-13, which are derived from Th2 cells,
play a critical role in asthmatic inﬂammatory response [120]. LPA
increases chemotaxis of Th2 cells, and it augments both IL-13
gene expression and secretion and transcriptional activity of the
IL-13 promoter [121,122]. More recently, increased ATX protein
was found in bronchoalveolar lavage ﬂuid (BALF) of asthmatic pa-
tients after allergen challenge [123]. Similar ﬁndings were also
found in mice when subjected to a triple-allergen model of asth-
ma (house dust mite, ragweed, and Aspergillus allergen). This in-
crease in ATX protein was correlated with increases in C22:5
and C22:6 species of LPA. Mice that were transgenic for ATX
had a more severe asthmatic phenotype and a signiﬁcant increase
in BALF IL-4 and IL-5 levels. This ATX-induced phenotype was
diminished with treatment of the S32826 analog ATX inhibitor
GWJ-A-23 [123].ATX has also been implicated in other lung diseases. The most
researched is idiopathic pulmonary ﬁbrosis (IPF), a chronic and
progressive ﬁbrotic diffuse lung disease occurring mainly in older
adults. LPA concentrations are increased in BALF of IPF patients
and bleomycin-treated mice, a murine model for IPF [124,125].
Conditional genetic deletion of ATX from bronchiolar epithelial
cells and macrophages diminishes the severity of bleomycin-in-
duced IPF [126]. Like in the murine asthmatic model, the ATX
inhibitor, GWJ-A-23, attenuated disease progression in bleomy-
cin-treated mice, implicating the potential value of ATX inhibitors
in treating IPF [123,126].
4.2. Rheumatoid arthritis
Rheumatoid arthritis is an autoimmune disorder characterized
by synovial inﬂammation and subsequent joint destruction. Hyper-
trophy and inﬂammation of the soft tissues around the synovial
joint are common ﬁndings. Macrophages are critically involved in
the pathogenesis of rheumatoid arthritis by producing a wide
range of pro-inﬂammatory cytokines and growth factors such as
IL-1, IL-6, IL-8, TNF-a and granulocyte macrophage colony-stimu-
lating factor (GM-CSF) [127,128]. LPA in synovial ﬂuid of rheuma-
toid arthritis patients stimulates cyclooxygenase-2 (COX-2)
expression. It synergizes with IL-1a and IL-1b to promote patho-
genesis [129], and upregulates IL-6 and IL-8 production [130]. Fur-
ther, TNF-a increases LPA3 mRNA expression in synoviocytes from
rheumatoid arthritis patients, which in turn modulates cytokine
production [130]. TNF-a drives increased ATX production from
synovial ﬁbroblasts in both mouse and human arthritic joints,
and anti-TNF-a treatment with inﬂiximab injections attenuated
this ATX expression in mice [131]. Furthermore, conditional genet-
ic ablation of ATX in mesenchymal cells in mice slowed disease
development [131]. Thus, rheumatoid arthritis is an ideal model
for studying of the interconnectivity of classical inﬂammation to
ATX/LPA signaling.
4.3. Obesity and atherosclerosis
Obesity, which is strongly associated with type 2 diabetes, is
considered to be a low-grade, chronic inﬂammatory state. This is
orchestrated by adipocytes in response to excess nutrients and en-
ergy through low-level induction of cytokines such as TNF-a, IL-1b
and chemokine C–C motif ligand 2 (CCL2) in the adipose tissue
environment [132]. In the presence of excess nutrients, a modiﬁed
milieu with an altered composition of immune cells favors an
unresolving pro-inﬂammatory situation in adipose tissue and sur-
rounding organs [132]. The roles that ATX/LPA signaling play in
obesity-mediated health manifestations are beginning to be eluci-
dated. ATX from white adipose tissue produces a signiﬁcant pro-
portion of extracellular LPA (Fig. 2). Mice carrying a null ATX
allele speciﬁcally in adipose tissue show a 38% reduction in plasma
ATX levels and an improvement in glucose tolerance levels [83].
Conversely, ATX expression is increased in adipose tissue of obese
and insulin-resistant mice and humans [83,133,134]. Transgenic
mice that overexpress ATX have reduced expression of brown adi-
pose tissue-related genes in peripheral white adipose tissue when
fed a high-fat diet and they accumulate more fat than wild-type
controls [135]. Furthermore, treatment of mice on a high-fat diet
with the LPA1/3 inhibitor Ki16425 improved glucose tolerance
compared to controls. Intraperitoneal injection of LPA acutely im-
paired both glucose tolerance and insulin secretion [136]. It is
not entirely clear from these studies if increases in ATX expression
promote or are a consequence of obesity, but there is evidence that
ATX inhibition could play a part in the management of obesity-in-
duced hyperglycemia.
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associated with a sedentary lifestyle. Historically, atherosclerosis
was a disease involving accumulation of lipids in the vessel walls
of arteries. However, recent research suggests that inﬂammation
plays an active role in all stages of atherosclerosis [137]. These
inﬂammatory processes are initiated in vessel-wall endothelial
cells in response to retained low-density lipoprotein (LDL). As this
LDL oxidizes, tissue macrophages derived from circulating mono-
cytes engulf these particles, but only partially process them. This
leads to deposition of oxidized cholesterol and phospholipids in
plaques in the arterial walls. These plaques promote the deteriora-
tion of the arterial wall resulting in the recruitment of even more
white blood cells to the affected area, which reinforces the cycle
[137]. Oxidation of LDL leads to local production of LPC, which is
subsequently converted into LPA by ATX [138]. LPA acting on endo-
thelial LPA receptors then elicits chemokine C–X–C motif ligand 1
(CXCL1)-dependent arterial monocyte adhesion. Furthermore, both
local and systemic administration of LPA accelerates atheroscle-
rotic progression in mice. Blocking LPA receptor signaling abro-
gated the recruitment of atherogenic monocytes in the presence
of CXCL1 [138]. Plasma LPA levels are signiﬁcant higher in patients
suffering from acute coronary syndrome (myocardial infarction
from either partial or complete blockage of coronary arteries) com-
pared to patients with either angina pectoris or normal coronary
arteries [139]. In these patients, LPA levels were signiﬁcantly high-
er in blood obtained from the affected coronary artery(ies) com-
pared to patient-matched peripheral blood samples [140]. This
suggests that ATX/LPA signaling may be involved in all stages of
artherosclerosis from silent plaque formation to acute symptoms
[139,140].
4.4. Liver and colonic disorders
The importance of ATX/LPA signaling in liver and colonic dis-
eases is rapidly becoming appreciated. Both plasma LPA and serum
ATX levels are increased in patients with chronic hepatitis C and
there is a positive correlation between ATX/LPA levels and the his-
tologic stage of ﬁbrosis [141]. These ﬁndings were complemented
with rat studies of liver injuries, which concluded that plasma
LPA and serum ATX levels are increased in chronic carbon tetra-
chloride-induced liver ﬁbrosis models, and acutely following
dimethylnitrosamine-induced injury or 70% hepatectomy [142].
Chronic hepatitis is a major risk factor for hepatocellular carci-
noma (HCC), and the relationship between hepatitis, HCC and
ATX will be discussed in greater detail in Section 5.
Other studies have validated serum ATX levels as being among
the best three biomarkers for the diagnosis of liver cirrhosis as
evaluated against deﬁnitive physical examination and diagnostic
imaging [143]. A mechanism for this increased serum ATXwas pro-
posed by Ikeda and Yatomi [69]. They demonstrate that in normal
liver, ATX is taken up from the hepatic sinusoid, an unique vascu-
lature, for degradation in liver sinusoidal endothelial cells. How-
ever, in ﬁbrosis, hepatic stellate cells are activated and produce
abundant extracellular matrices, blocking endothelial fenestrae
and impairing ATX intake. Therefore, the reduced clearance of
ATX from the circulation may explain the increase in serum ATX
in patients with liver ﬁbrosis [69].
Cholestatic pruritus is the sensation of itch due to liver diseases.
Interestingly, only ATX activity, but not histamine, tryptase, sub-
stance P, serum bile salts or l-opioid activity in serum correlated
with itch intensity of patients with cholestatic itch [144]. Pruritus
can be induced in a dose-dependent manner in mice by intrader-
mal injections of LPA via transient increases in Ca2+ concentrations
in neuronal cells [144], and is reversed by administration of the
LPA1/3 antagonist Ki16425 [145]. Subsequent work showed thatsuppressing ATX production helps in the management of these
conditions, and this is further discussed in Section 6.1.
Besides liver disorders, increased ATX expression has been
found in biopsies from patients with Crohn’s disease and ulcerative
colitis [71]. ATX mRNA levels are increased by at least ﬁve-fold in
inﬂammation progression from redness to ulceration. ATX expres-
sion in both the vascular endothelium and lymphocyte inﬁltration
were increased with successive treatments of dextran sodium
sulphate (DSS) in mice, a common colitis model. When treated
with the non-speciﬁc ATX inhibitor bithionol, these mice had
signiﬁcantly abrogated colitis activity and decreased numbers of
inﬁltrating lymphocytes [71]. Bithionol treatment attenuated the
thickening of the intestinal wall and shortening of the colon, signs
of both decreased inﬂammation and tissue remodeling [71]. This
work illustrated that ATX inhibition could be a novel treatment
option for inﬂammatory bowel diseases [71].
5. Recent insights into ATX and cancer
Ultimately, pathological ATX/LPA signaling is more complicated
than simply upregulated ATX production, and this has been best
studied in cancer. LPA signaling can be roughly divided into three
distinct domains: ATX activity, LPA receptors, and extracellular
LPA degradation by the ecto-activity of lipid phosphate phospha-
tases (LPPs) [7,60,146]. In many cancers, ATX protein is increased
leading to higher LPA levels in the tumor. Cancer cells also have in-
creased expression of LPA receptors on their cell surface compared
to normal and benign cells, and downregulated expression of LPPs
[7,60]. Thus, a triad of increased LPA production by ATX, increased
LPA receptor expression and decreased LPP activity to degrade LPA
on the cell surface creates the perfect storm for cancer prolifera-
tion, migration, metastasis and therapy resistance, which we have
previously reviewed [7,44,60,146]. It is not known if other ATX-
mediated inﬂammatory diseases follow the cancer model by
increasing LPA receptor expression and decreasing LPP activity, in
addition to increasing ATX production. However, the importance
of studying LPA signaling in terms of the whole-picture of the
ATX–LPA–LPP axis is becoming better appreciated [147,148].
Chronic inﬂammation is associated with both initiation and pro-
gression of many neoplastic conditions [149], and ATX may be a
player in the process. ATX/LPA signaling is positively correlated
with the invasive and metastatic potential of several cancers
including melanoma, breast cancer, ovarian cancer, thyroid cancer,
renal cell cancer, lung cancer, neuroblastoma, hepatocellular carci-
noma (HCC) and glioblastoma multiforme (see [44,150] and refer-
ences therein). HCC is particularly interesting because it often
develops in patients with chronic disease as a complication of liver
cirrhosis [151]. This is especially true for hepatitis C, which ac-
counts for 25% of all HCC cases and is themost signiﬁcant risk factor
for HCC [152]. Microarray analysis of liver samples from hepatitis C
and HCC patients showed an increase in ATX mRNA levels com-
pared to normal patients [153]. This work was followed with ATX
immunohistochemical analysis of HCC biopsies derived from differ-
ent etiologies, and staining was heaviest in patients with histories
of either hepatitis C, hepatitis B or non-alcoholic steatohepatitis
(NASH) compared to HCC patients with otherwise normal livers
and without identiﬁed risk factors [154]. ATX staining was most
positively correlated to both the degree of liver inﬂammation and
cirrhosis regardless of etiology [154]. In vitro, ATX expression was
elevated in HCC lines Hep3B and Huh7 compared to the well-differ-
entiated HepG2 HCC cell line, normal embryonic CL-48 liver cells
and primary hepatocyte cultures [154]. ATX expression could be
further increased in Hep3B andHuh7 cell lines upon treatmentwith
TNF-a through a nuclear factor-kappa B (NF-jB)-dependent mech-
anism, but not for HepG2 or CL-48 cell lines [154].
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signaling in cancer [34–43], the regulation of ATX expression is
poorly understood, although some progress has been made. Galec-
tin-3, a b-galactoside bindingprotein known to increase the invasive
potential of cancer cells, increases ATX expression at the transcrip-
tional level bymodulating the expression of the transcription factor
Nuclear Factor of Activated T-cell 1 (NFAT1) [155]. Silencing galec-
tin-3 suppresses NFAT1 protein expression, which in turn reduces
ATX expression. Re-expression of ATX in galectin-3-silenced cells
rescues angiogenesis, tumor growth and metastasis in vivo [155].
Similar work has been done in mantle cell lymphoma, where
knock-down of the transcription factor SOX11 suppresses ATX pro-
duction [156]. In breast cancer specimens, there is a positive corre-
lation between nuclear tyrosine-phosphorylated signal transducer
and activator of transcription factor 3 (pStat3) and ATX. In primary
cultures of breast cancer specimens from patients, inhibition of
pStat3 or reduced Stat3 expressiondeceases bothATX levels and cell
migration [157]. However, the tumor is a heterogeneous environ-
ment composed of many different cell types including ﬁbroblasts,
endothelial cells and leukocytes in addition to cancer cells. There
are also a host of soluble molecules in the tumor and this heteroge-
neity adds another layer of complexity to ATX/LPA signaling. Pop-
nikolov et al. showed by that ATX and LPA3 staining correlate
positively with cancer aggressiveness [158]. However, this work is
particular novel because the authors showed that ATX staining is
predominantly stromal, whereas cancer epithelial cells stain heavi-
est for LPA3 [158]. In support of this observation,we showed ina syn-
geneic, orthotopic model of breast cancer that the 4T1 cancer cells
express negligible ATX compared to the surrounding mammary fat
pad [159]. As the tumor grows, the surrounding mammary fat pad
signiﬁcantly increases the production of mRNA and protein for
ATX, suggesting that ATX is a mediator in the cross-talk between
cancer cells, the tumor stroma and the mammary fat pad [159].
We have preliminary evidence to show that cytokines from the
growing tumor stimulate stromal tissue to increase ATX production,
and thisATX fuels tumorprogression inaparacrine fashion. Pharma-
cological inhibition with a novel ATX inhibitor, ONO-8430506, (see
Section 6.3) reduces mRNA for the pro-inﬂammatory IL-1b and IL-
6 cytokines compared to vehicle treatment [159]. The detailed
mechanisms for these effects have yet to be determined, however
we present a novel model of ATX signaling in cancers which endog-
enously express low levels of ATX in Section 7.2. Interestingly, it is
estimated that obesity contributes to at least 20 percent of cancer
deaths by inﬂuencing cancer onset [160,161]. Our results demon-
strate that production of ATX in adipose tissue can explain at least
part of this linkage between adiposity and breast cancer.
ATX/LPA signaling in cancer is also well known to promote che-
motherapy and radiotherapy resistance [7]. Furthermore, others
have recently shown that endothelial-derived ATX activity in renal
cell carcinoma promotes renal tumorgenesis and acquired resis-
tance to sunitinib through an IL-8-mediated mechanism [162].
ATX/LPA signaling is physiologically response to promote wound-
healing following injury. Signiﬁcantly, cytotoxic cancer therapy
and ionizing radiation essentially produce an injury to the tumor
and adjacent tissues. In the process of self-repair, affected tissues
use ATX/LPA signaling to increase the expression of survival path-
ways, which reduces the subsequent effectiveness of the therapy.
Hence, inhibiting ATX production of LPA should block this vicious
cycle of injury and tissue repair and therefore have great utility
in abrogating cancer therapy resistance.
6. Development and implementation of ATX inhibitor therapies
As an extracellular enzyme, ATX is a very attractive drug target.
Considerable attention has been given towards designing potentinhibitors of ATX, and this has been reviewed previously
[55,163,164]. We will now discuss only those inhibitors that have
been used primarily in vivo. We will begin by summarizing ATX
targeting strategies through indirect means, the development of
both lipid- and non-lipid competitive ATX inhibitors and the cur-
rent methods being employed to develop more effective ATX
inhibitors.
6.1. Indirect approaches to targeting ATX
Among the ﬁrst inhibitors of ATX activity was L-histidine, re-
ported to have an ATX binding afﬁnity (Ki) of about 1 mM
in vitro, with 10 mM concentrations required to block ATX-stimu-
lated migration in melanoma cells by 90% [165]. L-histidine inhibits
ATX activity in a non-competitive manner in part by chelating me-
tal cations required for optimum catalytic rates since L-histidine
inhibition can be overcome by addition of Zn2+ to culture media
[165]. Later work showed L-histidine administered intraperitone-
ally to rats limits thioacetamide-induced liver ﬁbrosis [166].
Few studies have focused on inhibiting ATX production at the
level of transcription. One such study showed that cholera toxin
inhibits human hepatocarcinoma cell proliferation in vitro by sup-
pressing ATX production through a TNF-a-dependent mechanism
[167]. Cholera toxin treatment increases the expression of the
anti-inﬂammatory cytokines IL-4 and IL-10, which were previously
known to suppress ATX mRNA levels [168]. Knockdown of ATX
expression with siRNA abrogated cholera-toxin suppression of
Hep3B and Huh7 HCC cell growth [167]. Another study showed
that oral administration of prednisolone, the bioactive form of
the anti-inﬂammatory corticosteroid prednisone, signiﬁcantly de-
creased serum ATX levels in a dose-dependent manner in patients
being treated for autoimmune skin diseases [169]. In these pa-
tients, it is unclear if ATX suppression contributed to symptom re-
lief since tapering of the prednisolone dosage led to a rebound in
serum ATX levels independently of disease severity. However,
the authors proposed that serum ATX levels could be used as a
marker of compliance and/or efﬁcacy of steroid therapy [169]. Fi-
nally, rifampicin, an inhibitor of DNA-dependent RNA polymerase,
lowers transcription of ATX mRNA in the treatment of cholestatic
pruritus. In these patients, removal of rifampicin treatment led to
both reoccurrence of pruritus and a return of ATX levels to pre-
treatment levels [170]. However, all of these treatment options
that decrease ATX protein expression appear to be effective only
in speciﬁc diseases. Instead, most ATX-targeting therapies are de-
signed to inhibit ATX activity and LPA production so as to have util-
ity in multiple conditions.
6.2. Lipid-mimetics as ATX inhibitors
To be effective as a therapy, drugs needs to have good bioavail-
ability, potency and have a sufﬁcient safety proﬁle. For ATX, ﬁnding
an inhibitor that meets these criteria began around 2006, when the
very ﬁrst synthetic competitive ATX inhibitors were reported.
These were analogs of cyclic phosphatidate (cPA) with a Ki of
approximately 100 nM (Fig. 4). These compounds signiﬁcantly
inhibited melanoma cell metastasis in tail vein-injection mouse
models [171] and inhibited C-ﬁber stimulation caused by chronic
inﬂammation in rat neuropathic pain models [172]. However,
cPA analogs are also weak agonists of LPA receptors, which limit
their utility [55].
The next group of lipid-mimetic ATX inhibitors developed in
2009 were a-bromophosphonates (BrP-LPA). The anti-BrP-LPA iso-
mer had IC50 of 22 nM in plasma, which was more potent than for
syn-BrP-LPA [173] (Fig. 4). BrP-LPA is also a pan-antagonist of
LPA1–3, and has been used to reduce MDA-MB-231 breast tumor
growth in orthotopic xenograft models [173] and A549 lung cancer
Fig. 4. Structure of LPA compared to structures of major ATX inhibitors that have been used experimentally in vivo.
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murine glioma models using GL-261 cells had radiosensitizing ef-
fects on tumor vasculature and delayed tumor growth by 7 days
compared to mice treated with irradiation alone [175]. This study
was one of the ﬁrst to demonstrate that ATX inhibitors have poten-
tial as an adjuvant therapy for cancer. A later report using a colla-
gen-induced arthritis mouse model showed that BrP-LPA
attenuated disease symptoms by diminishing synovial LPA signal-
ing. Histopathological analysis of joints of the mice indicated
marked decreases in inﬂammation and synovial hyperplasia [176].
Nevertheless, lipid-analog ATX inhibitors tend to have poor bio-
availability largely because of the hydrophobic acyl tail [164]. The
inhibitor S32826, a benzyl phosphonic acid derivative, best dem-
onstrates this effect (Fig. 4). Despite having a very low nM IC50
in vitro, the presence of a long chain means the drug has a very high
lipophilicity and cannot suppress circulating ATX activity for more
than a few minutes [33]. Analogs of S32826 have been developed
such as GWJ-A-23 by shortening the lipophilic chain and adding
a-halo- or a-hydroxy-substituents to increase solubility (Fig. 4),which was discussed in Section 4.1. However, most of these com-
pounds are less potent as ATX inhibitors compared to S32826
[177]. Hence, efforts have shifted over the last couple of years to
ﬁnding and developing ATX inhibitors that are more soluble and
non-lipid based.
6.3. Small non-lipid molecule as ATX inhibitors
There are numerous small non-lipid molecules that have been
discovered and modiﬁed to inhibit ATX activity through screening
large libraries of compounds, the history of which has been re-
viewed recently [163,164]. Unlike lipid analogs, these inhibitors
tend to have better oral bioavailability due to their decreased
hydrophobicity and they are unlikely to be degraded rapidly by
endogenous hydrolytic pathways [178]. PF-8380, a piper-
azinylbenzoxazolone derivative, was developed by Pﬁzer from
compound library screening and optimization (Fig. 4). It has an
IC50 of 2.8 nM against recombinant human ATX and 101 nM for hu-
man whole blood. It was the ﬁrst reported ATX inhibitor to reduce
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pouch models, 30 mg/kg PF-8380 inhibited inﬂammatory hyperal-
gesia with the same efﬁcacy as 30 mg/kg naproxen, a routinely
used non-steroidal anti-inﬂammatory drug (NSAID) [32]. At this
concentration, PF-8380 maximally reduced LPA levels in both plas-
ma and at the site of inﬂammation. Like BrP-LPA, PF-8380 had
radio-sensitizing effects in glioblastoma multiforme heterotopic
mouse models, delaying tumor growth by at least 20 days
[175,179]. In this study, inhibition of ATX by PF-8380 abrogated
radiation-induced activation of Akt and subsequently decreased
tumor vascularity and tumor growth [179]. We have recently
worked with another potent ATX inhibitor, ONO-8430506 (Patent
WO20120052227), currently in development by Ono Pharmaceuti-
cals Ltd. (Osaka, Japan), This is a tetrahydrocarboline derivative,
which after oral gavage at 10 mg/kg suppressed plasma ATX activ-
ity by at least 90% at 6 h after administration in mice [159]. Plasma
LPA levels were also signiﬁcantly suppressed, with some unsatu-
rated species like C16:1 and C20:5 remaining non-detectable at
both 6 and 24 h after ONO-8430506 administration. ONO-
8430506 suppressed initial tumor growth and subsequent lung
metastasis by up to 60% in a mouse syngeneic and orthotopic
breast cancer model using Balb/c/4T1 cancer cells. A similar proﬁle
for the decrease in LPA species was achieved in tumors [159].
These ﬁndings conﬁrm that ATX produces most extracellular LPA
and that ATX inhibition decreases LPA concentrations in tissues
and breast tumors as well as in the plasma [32,159].
6.4. Strategies for ATX inhibitor design
To date the most common technique for ATX inhibitor discovery
and design is to screen huge libraries of compounds by using ATX
substrates such as Fluorescent Substrate-3 (FS-3), and then modify
hits to further increase potency. FS-3 is a ﬂuorgenic substrate that
is a doubly-labeled analog of LPC. The ﬂuorophore is quenched
through intramolecular energy transfer, and hydrolysis of the sub-
strate by ATX produces an increase in ﬂuorescence [13]. The ﬁrst
studies employing this technique in the search for non-lipid ATX
inhibitors appeared in 2008 and identiﬁed several inhibitors with
an IC50 in the lM range [180,181]. Later work using compounds
from these studies developed nine pharmacophores for ATX inhibi-
tion and the results of these analyses were used to screen the Na-
tional Cancer Institute’s (NCI) open chemical repository database
to prioritize screening efforts [178]. This led to the identiﬁcation
of several novel compounds with an IC50 in the low to high lM
range [178,182].
Since these initial reports, the crystal structure of ATX has been
solved enabling for structure–activity relationship studies and
more rational-design approaches towards optimizing inhibitors.
The interpretation of this structural data and its application to
inhibitor design has been previously reviewed [18,164,183–185],
but brieﬂy the most signiﬁcant ﬁnding has been that ATX has a
hydrophobic tunnel formed from the interactions between its
somatomedin-B-like 1 (SMB1) and the central phosphodiesterase
(PDE) domains. This tunnel connects the hydrophobic pocket,
which accommodates the tail of a bound lipid substrate, and the
catalytic site. It is believed that the tunnel may function as both
a binding site for substrates as well as a release site for products,
and hence represents an ideal target for inhibitor design and/or
optimization. The ﬁrst study to use this approach was by Kawagu-
chi et al. to identify a thiazolone derivative, which had an IC50 for
ATX activity of 180 nM, from a 81600-compound library [183]. The
authors were able to design from the crystal structure of ATX com-
plexed with this inhibitor a series of side-chain modiﬁcations that
led to a derivative compound named 3BoA with an IC50 of 13 nM
[183]. More recent studies by Fells et al. have combined large li-
brary screening results using the crystal structures of ATX with vir-tual screening tools to discover additional novel ATX inhibitors
[186,187]. This approach has identiﬁed a common aromatic sulfon-
amide structural motif among potent inhibitors that targets the
hydrophobic pocket of ATX, which accommodates the hydrocarbon
tail of LPC/LPA [186,187]. Similar techniques are expected to lead
to the rapid development of ATX inhibitors for subsequent testing
and development in vivo.7. Perspective and concluding remarks
In this section, we will present considerations for effective
pharmacological ATX/LPA signaling inhibition and highlight both
major concerns and expectations for the introduction of inhibitors
into clinical practice. Finally, we will present new insights into ATX
production in carcinomas consistent with the roles of ATX in other
inﬂammatory diseases.
7.1. Considerations for the inhibition of ATX/LPA signaling
Designing antagonistic ligands against cell-signaling receptors is
especially tricky since such ligands may be partial agonists in sec-
ondary tissues or have agonistic properties though redundant and/
or related receptors. This problem is best highlighted by the use of
tamoxifen. Tamoxifen, a selective estrogen receptor-a modulator
(SERM), which is used as an antagonist to block (pre)cancerous cell
division in breast tissue as part of the treatment regimen for both
early and advanced estrogen-receptor-a positive breast cancers.
Unfortunately, tamoxifenhas partial agonist activity in the endome-
trium,which in turn increases the risk of endometrial cancer. Conse-
quently, tamoxifen is not used in patients for greater than ﬁve years
unless they have already undergone a hysterectomy [188]. This ago-
nist activity in endometriumcanbemediated through theG-protein
coupled estrogen receptor GPR30 [189]. There are at least six LPA
receptors that have evolved from different ancestral genes with
LPA1–3 belonging to the Edg receptor family. LPA4–6 aremore closely
related to the purinergic G-protein coupled receptors [76]. The com-
plexity, heterogeneity and redundancy in these receptors present
considerable difﬁculties compared to those of tamoxifen for design-
ing effective LPA receptor antagonists devoid of unintended side ef-
fects (Fig. 1B).
As discussed earlier, ATX KO mice die in utero and the pheno-
type can be partially reversed by exogenous addition of LPA to ex-
plant embryos [77]. This emphasizes the critical role of LPA-
mediated signaling, presumably through LPA receptors. To study
this, KO mice for all the LPA receptors have been generated and
yet all models are viable with no or minimal phenotypes. Even
more strange, most LPA signaling is mediated through LPA1–3,
and yet despite creating all the double KO combinations of these
receptors as well as the triple KO, these mice are viable
[6,190,191]. These ﬁndings underscore the incredible redundancy
of LPA-receptor signaling pathways (Fig. 1B) and also suggest there
may be other receptors that can mediate LPA signaling.
The current state of development of LPA receptor inhibitors was
reviewed recently by Budd and Qian [96]. In summary, most efforts
from the pharmaceutical industry have been on the development
of LPA1-selective, LPA2-selective, and LPA1/3 dual antagonists
(LPA1 and LPA3-mediated signaling is extremely overlapping –
see Fig. 1B). However, to address some of the issues previously
highlighted, there is a debate as to whether a more effective ap-
proach would be to develop pan-LPA receptor antagonists [96].
Ultimately, drug design approaches need to balance efﬁcacy with
safety, and a hypothetical pan-antagonist is more likely to have
cross-reactivity with other unintended G-protein coupled recep-
tors than an antagonist designed speciﬁcally to interact with one
or two receptors. Such antagonists would likely have to be deliv-
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systemic side effects compared to simpler oral, subcutaneous and/
or intravenous administration options [96].
Alternatively, another solution is to target LPA directly with a
monoclonal antibody, similar to the use of inﬂiximab against
TNF-a to treat autoimmune diseases. Such an antibody has been
developed to block LPA from interacting with its receptors, and it
has been shown to improve spinal cord injury outcomes in zebra-
ﬁsh and mouse models by reducing glial inﬂammation and neu-
ronal cell death [192]. Likewise, ATX inhibitors may be a more
effective and safer means of targeting LPA signaling than LPA
receptor antagonists since ATX produces virtually all of the extra-
cellular LPA. With ATX, there is only one target for inhibition ver-
sus multiple LPA receptors. With effective ATX inhibition, plasma
LPA levels rapidly fall and remain inhibited with sustained ther-
apeutic dosing [32,159]. Most disease conditions correlated with
ATX/LPA signaling rely on sustained elevated LPA levels brought
about by increased ATX protein production. LPA levels in physio-
logical processes seem not to be as high as levels in cancer and
other inﬂammatory-mediated diseases. This suggests that ATX
inhibition is more likely to have therapeutic effects by lowering
LPA levels below that required for pathogenesis, but still leave
for sufﬁcient LPA production to meet physiological requirements.
Currently, ATX inhibitors are still in the pre-clinical phase of
development. Most of the latest inhibitors are non-LPA-mimics,
which have improved bioavailability proﬁles and no partial-ago-
nist reactivity with LPA receptors. We predict that these inhibitors
will have great potential either on their own or as adjuvant ther-
apy, particularly for treating cancer. We also predict that ATX inhi-
bition could be synergistic with conventional anti-inﬂammatory
therapy given that ATX inhibitors have been shown to be equally
effective as NSAIDs in reducing inﬂammation in animal models
[32]. In fact, adding an ATX inhibitor might lower dosage require-
ments for NSAIDs, or a chemotherapeutic agent. This could provide
beneﬁts by improving the tolerance of patients to the treatment.
7.2. ATX as a tumor microenvironment promoter of cancer progression
and cancer therapy resistance in carcinomas
As described throughout this article, ATX is elevated inmany dif-
ferent tumors, implicating ATX as a promoter of cancer progression.
These results, coupled with the initial identiﬁcation of ATX as a se-
creted enzyme in melanoma cell cultures, has given rise to the
impression that ATX is generally produced in cancer by an autocrine
mechanism [42]. Evidence for this model of ATX production is well
supported in melanoma, a cancer of melanocytes which are derived
from the embryonic neural crest [193], as well as gliomas which de-
rived from nervous tissue [194,195]. However, this may not neces-
sarily be the case for other cancers namely carcinomas, which are
cancers of epithelial cells and comprise about 90% of all cancers
[196]. Even thoughhigh levels of ATXare often found inprimary car-
cinomas andmetastatic tumors compared to normal or benign spec-
imens, this does not mean that the cancer cells produce ATX. When
discussing tumors, the terms ‘‘tumor cells’’ and ‘‘cancer cells’’ are of-
ten used interchangeably, ignoring the heterogeneous cell popula-
tions that comprise tumors. Tumors are composed of not just
cancer cells but also of stroma, which include ﬁbroblasts, endothe-
lial cells and leukocytes. All of these cells are surrounded by a host
of signaling molecules that facilitate communication between dif-
ferent cell populations [197–199]. This model of interaction be-
tween different cell populations is termed the tumor
microenvironment and its importance inunderstanding cancer biol-
ogy is rapidly gaining momentum [197–199].
In this review, we have illustrated that ATX production by ﬁbro-
blasts and endothelial cells promotes chronic inﬂammation-drivendiseases like rheumatoid arthritis and atherosclerosis [66,140]. Be-
cause cancer is also a chronic inﬂammatory condition, it is plausi-
ble that cancer progression and cancer therapy resistance can be
fueled by ATX from non-cancer cell sources, such as the tumor
stroma or surrounding tissue. This was illustrated earlier by ATX
from endothelial cells promoting resistance of renal cell carcinoma
to treatment with sunitinib [162]. To further support this, we have
assessed both ATX mRNA and activity in MDA-MB-231, MDA-MB-
468 and MCF-7 cells (unpublished results) and mouse 4T1 breast
cancer cell lines [159]. These cancer cells produce insigniﬁcant
quantities of ATX compared to breast ﬁbroblasts and breast adi-
pose tissue. Adipose tissue is known to produce high levels of
ATX [134,135] (Fig. 2). As mentioned in Sections 5 and 6, we found
that 4T1 breast cancer cells express thousands of fold less ATX
mRNA and hundreds of fold less ATX protein than the mammary
fat pads of Balb/c mice. In fact, in the Broad Institute’s Cancer Cell
Line Encyclopedia [200], breast cancer cell lines are amongst the
lowest expressers of ATX mRNA (Fig. 5A). However, in light of high
ATX expression in surrounding breast adipose tissue (Fig. 2), breast
cancers can easily acquire LPA from breast tissue stroma-derived
ATX. The growing tumor containing 4T1 cancer cells in our mouse
model further induces the production of ATX mRNA and protein in
the surrounding mammary fat pad [159]. We also conﬁrmed by
immunohistochemistry that the majority of ATX staining in these
tumors was associated with stromal cells rather than cancer cells
[159]. This ﬁnding could explain why using ATX shRNA in 4T1 cells
has no signiﬁcant effect in slowing primary tumor growth [201].
The growth and viability of the 4T1 cancer cells were not af-
fected in vitro when treated with the ATX inhibitor ONO-
8430506. However, when 4T1 cells were injected into mice,
ONO-8430506 decreased both tumor growth and metastasis
[159]. Hence, the utility of an ATX inhibitor for treating cancer
need not be restricted to those cancer cells that produce ATX
themselves. Delineating which cells express the bulk of ATX with-
in a tumor and what signaling molecules drive this production are
currently under study. Our preliminary evidence shows that
breast ﬁbroblasts signiﬁcantly increase ATX expression in re-
sponse to stimulation by cytokines like TNF-a and cancer-cell de-
rived growth factors like EGF and platelet-derived growth factor
(PDGF).
In light of these observations, we propose that ATX in some
carcinomas, like breast cancer, comes from non-cancer cells in
the tumor (Fig. 5B). This expression can be increased further as
the cancer progresses, since this establishes a pro-inﬂammatory
milieu where leukocytes are further recruited into the tumor
microenvironment. Similarly, chemotherapy and radiotherapy
provoke a wound-healing reaction, in which the secretion of
pro-inﬂammatory cytokines (TNF-a, IL-1b and IL-6 for example)
from leukocytes and cancer-cell derived growth factors (EGF and
PDGF) further induce ATX production and secretion from the tu-
mor stroma. This vicious cycle, which produces LPA, promotes
cancer cell survival, growth and further treatment resistance.
Hence, blocking this vicious cycle by inhibiting ATX activity and
LPA signaling breaks this cross-talk between cells in the tumor
microenvironment and thus cancer progression. Future research
into ATX production and cancer should take into account how
the tumor stroma and the surrounding organ inﬂuences tumor
development, metastasis and therapy resistance.
In conclusion, blocking the effects of inﬂammation in stimulat-
ing the production of LPA by ATX should provide a novel treat-
ment for cancers by decreasing tumor growth, metastasis and
the development of resistance to cancer treatments. Thus, we
hope that inhibitors of ATX/LPA signaling will quickly move into
clinical trials and eventual clinical practice ahead of the silver
anniversary of the discovery of ATX.
Fig. 5. (A) ATX mRNA levels in different cancer cell lines as retrieved from the Cancer Cell Line Encyclopedia [200] from the Broad Institute, ID # 5168. At the time of
publication, the Cancer Cell Line Encyclopedia contains gene expression data for 1046 cancer cell lines. The number of cell lines per cancer type assayed is indicated in the x-
axis. RMA, robust multi-array average (y-axis); AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; DLBCL, diffuse large B-cell
lymphoma; NSC, non-small cell. (B) Proposed model for ATX as a tumor microenvironment promoter of cancer progression and therapy resistance in breast carcinomas and
other cancers in which the cancer cells produce little ATX themselves. Tumor stroma and/or tissue surrounding the growing tumor is composed of cell populations such as
ﬁbroblasts and endothelial cells, which secrete ATX into the tumor microenvironment. As a wound-healing response, autocrine/paracrine production of LPA by ATX evolves to
help the tissue recover from damage (green arrows). However, in cancer the inﬂammatory response and ATX secretion promote cancer cell growth, migration and survival
against cancer therapy. This and additional therapy further increases the pro-inﬂammatory milieu of the tumor microenvironment, leading to the additional recruitment of
leukocytes into the tumor. Pro-inﬂammatory cytokines like TNF-a, IL-1b and IL-6 from leukocytes and growth factors from cancer cells like EGF and PDGF can further
stimulate ATX production from tumor stroma (red arrows). We propose a similar model for other tumors, except that in many cases the cancer cells produce signiﬁcant
quantities of ATX (see Panel A).
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